Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels as compared with therapy based on protease inhibitors
=============================================================================================================================================================================================================

* Alexander O. Pasternak
* Jelmer Vroom
* Neeltje A. Kootstra
* Ferdinand W.N.M. Wit
* Marijn de Bruin
* Davide De Francesco
* Margreet Bakker
* Caroline A Sabin
* Alan Winston
* Jan M. Prins
* Peter Reiss
* Ben Berkhout
* on behalf of The Co-morBidity in Relation to Aids (COBRA) Collaboration and the AIMS Cohort Study

## Abstract

**BACKGROUND** It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress HIV replication. Here, we report the results of two cross-sectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).

**METHODS** CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n=100, n=124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4+ count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically-measured adherence to ART.

**RESULTS** In both cohorts, levels of CA HIV RNA and DNA strongly correlated (*rho*=0.70 and *rho*=0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (padj=0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (padj=0.048 and padj=0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals.

**CONCLUSIONS** All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size.

## Introduction

In individuals who are able to adhere to combination antiretroviral therapy (ART), therapy suppresses HIV replication, restores immune function, and prevents the development of AIDS [1]. More than 20 different antiretroviral drugs belonging to six main classes are currently approved for clinical use [2]. Depending on the class, these drugs block different steps of the HIV replication cycle, such as reverse transcription, proviral integration, or virus particle maturation. Current ART regimens typically consist of two nucleotide or nucleoside reverse transcriptase inhibitors (NRTIs) and a third drug of another class, e.g., a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (INSTI).

Despite the efficient suppression of HIV replication, ART is not curative and has to be sustained lifelong. Persistence of viral reservoirs forms the major obstacle to an HIV cure [3]. Viral reservoir markers, such as low-level HIV RNA in plasma (residual viremia) and cell-associated (CA) HIV DNA and RNA, can be measured in most treated individuals with plasma HIV RNA suppressed to below the limit of quantification of commercial assays [4-8]. Although HIV latent reservoirs persist primarily by cell longevity and proliferation [9-11], replenishment of the reservoirs by residual virus replication despite ART has been proposed as an alternative mechanism of HIV persistence [12-14]. The latter possibility remains a matter of longstanding debate in the HIV research field [15]. Residual HIV replication can result from insufficient penetration of antiretroviral drugs into tissues and anatomic sanctuaries, causing reduced local drug concentrations in tissue sites [16, 17]. However, most (but not all) studies could not demonstrate any measurable virus evolution in peripheral blood and tissues of ART-treated individuals [18-20]. This lack of significant virus evolution on ART is considered one of the strongest arguments against residual HIV replication. On the other hand, a transient increase in episomal HIV DNA has been demonstrated in a number of trials of ART intensification with raltegravir, an INSTI [21, 22]. This accumulation of unintegrated HIV DNA, observed upon blocking integration, revealed ongoing integration events prior to intensification. Because all other antiretroviral drug classes act upstream of INSTIs, this implies that complete rounds of HIV replication (infection of new cells) had been ongoing pre-intensification. However, no decrease in residual HIV viremia could be demonstrated in these and other intensification trials [23-25].

It is also a matter of debate whether different ART regimens are equally potent in suppressing residual HIV replication. All current antiretroviral drugs act by preventing the infection of new cells and are not expected to inhibit HIV RNA transcription or virus production in the long-lived reservoir cells that were infected prior to ART initiation, or in the progeny of such cells. Therefore, if regimens are equally potent in stopping the infection of new cells, one would not expect to detect a difference in residual viremia or CA RNA levels between ART regimens. Consequently, finding such a difference would suggest that some regimens are more potent in suppressing residual replication than others, arguing that virus suppression is less complete with at least some of the regimens. A number of studies reported lower levels of residual viremia in individuals treated with NNRTI-based, compared to PI-based, ART regimens ([26, 27], reviewed in [28]). However, to date, few studies have compared levels of CA HIV reservoir markers between different ART regimens. Here, we cross-sectionally measured CA HIV RNA and DNA in two cohorts of individuals receiving suppressive ART containing two NRTIs and either a NNRTI or a PI.

## Results

### CA HIV RNA and DNA in the COBRA cohort

We measured CA HIV unspliced RNA and total HIV DNA in peripheral blood mononuclear cell (PBMC) samples from participants of the COmorBidity in Relation to AIDS (COBRA) cohort [29]. COBRA is a cohort of HIV-infected individuals aged 45 or older with sustained HIV suppression on ART recruited from two large European HIV treatment centers in Amsterdam and London. Of 132 COBRA participants with available PBMC samples, 100 were treated with ART that consisted of two NRTIs plus either one NNRTI (n=58) or one ritonavir-boosted PI (n=42) and were included in the analysis. Samples were obtained between April 2011 and December 2014. Table 1 shows the participant characteristics, grouped according to the treatment regimen. In brief, 95% were male and the median age was 55 years (interquartile range, 51-61 years). Ninety-eight participants had undetectable plasma HIV RNA (<50 copies/mL) and two had detectable but low levels (66 and 90 copies/mL). Participants had a median of 118 (62-163) months of cumulative and 99 (47-146) months of continuous virological suppression on ART prior to the measurements and had been treated with their current NNRTI or PI regimen for a median of 69 (38-116) months. The duration of virological suppression on ART and the duration of current regimen prior to the measurements were significantly different between NNRTI- and PI-treated participants (cumulative suppression: median of 137 vs. 90 months, respectively, p=0.004; continuous suppression, median of 118 vs. 62 months, respectively, p=0.001; current regimen: median of 99 vs. 48 months, respectively, p<0.0001).

View this table:
[Table 1.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/T1)

Table 1. 
Characteristics of participants treated with NNRTI- and PI-based ART regimens.

The median CA HIV RNA and total HIV DNA levels in the COBRA cohort were 2.15 (1.58-2.52) log10 copies/μg total RNA and 2.50 (1.84-2.77) log10 copies/106 PBMC, respectively. Figure 1A shows correlations of current CD4+ count, CD4+ count nadir, plasma HIV RNA zenith, and duration of continuous virological suppression prior to the measurements, with CA HIV RNA and DNA. Significant correlations with both HIV RNA and DNA were observed for the plasma HIV RNA zenith (rho=0.22, p=0.04 and rho=0.36, p=0.0004, respectively), but not for any other variable. Duration of cumulative virological suppression and duration of the current regimen were also not associated with either CA HIV RNA or DNA (cumulative suppression: rho=0.04, p=0.68 and rho=-0.06, p=0.60; current regimen: rho=0.02, p=0.82 and rho=0.02, p=0.87). Furthermore, CA RNA and DNA strongly correlated (rho=0.70, p<0.0001) and both markers were lower in NNRTI-than in PI-treated participants (CA RNA: 1.78 (1.58-2.29) vs. 2.36 (1.55-2.65) log10 copies/μg total RNA, p=0.03; total DNA: 2.46 (1.78-2.64) vs. 2.60 (1.93-2.90) log10 copies/106 PBMC, p=0.07).

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/03/26/2021.03.25.21254129/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/F1)

Figure 1. 
Associations of clinical and virological variables, time of virological suppression, and ART regimens (NNRTI-based vs. PI-based) with the levels of cell-associated HIV unspliced RNA (US RNA) and total HIV DNA in (A) COBRA cohort (n=100) and (B) AIMS cohort (n=124). Units of measurement are: US RNA: log10 copies/μg total RNA, total DNA: log10 copies/106 PBMC, CD4 count and CD4 nadir: cells/mm3, plasma HIV RNA zenith: log10 copies/mL. Levels of significance were calculated by Spearman correlation analyses or Mann-Whitney tests, as appropriate.

To assess the association of CA HIV RNA and DNA with ART regimens, we built multivariable generalized linear models, adjusted for a number of demographic and clinical variables (Figure 2A, Table S1). Higher plasma HIV RNA zenith and PI-based ART regimen remained significantly associated with higher levels of both CA HIV RNA and DNA in the multivariable analysis (plasma HIV RNA zenith: padj=0.02 and padj=0.0001, respectively; ART regimen: padj=0.02 and padj=0.048, respectively).

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/03/26/2021.03.25.21254129/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/F2)

Figure 2. 
Regression analyses to identify variables associated with cell-associated HIV unspliced (US) RNA and total HIV DNA levels in (A) COBRA and (B) AIMS cohorts. Effect sizes and 95% confidence intervals for US RNA are plotted as log10 copies per microgram of total cellular RNA and for total DNA as log10 copies per million PBMC. Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p values <0.1 in the univariable analyses were included in the multivariable analyses.

### CA HIV RNA and DNA in the AIMS cohort

Having established an association between CA HIV RNA and DNA and the ART regimen in the COBRA cohort, we sought to validate these observations in another cohort. To this end, we used PBMC samples from participants of a randomized controlled trial that investigated the effects of a behavioral intervention to increase adherence to ART (Adherence Improving Self-Management Strategy, AIMS) [30]. Participants for this trial with electronically measured adherence had been recruited from HIV-infected individuals on ART visiting the outpatient clinic of the Academic Medical Center (Amsterdam, Netherlands). Samples were obtained between March 2005 and February 2007. Of 147 AIMS participants with available PBMC samples, 124 were treated with ART that consisted of two NRTIs plus either one NNRTI (n=88) or one PI (n=36) and were included in the analysis. Table 1 shows the participant characteristics. In brief, 88% were male and the median age was 46 years (interquartile range, 40-54 years). Median adherence to ART was 91% (66-100%). 107 out of 124 participants had undetectable plasma HIV RNA (<50 copies/mL) and 17 had detectable but low levels (range, 52-366 copies/mL). The duration of cumulative (median, 47 (25-88) months) and continuous (40 (17-72) months) virological suppression on ART prior to the measurements, as well as the duration of current NNRTI or PI regimen (median, 26 (10-46) months), were shorter in the AIMS compared to the COBRA cohort. As in the COBRA cohort, the duration of continuous virological suppression on ART prior to the measurements and the duration of current regimen were significantly different between NNRTI- and PI-treated participants (continuous suppression, medians of 45 vs. 20 months, respectively, p=0.01; current regimen, medians of 39 vs. 13 months, respectively, p<0.0001). In addition, low-level plasma HIV RNA was detectable more frequently in PI-treated than in NNRTI-treated participants (25.0% vs. 9.1%, p=0.04). Other variables, including adherence to ART, did not differ between NNRTI- and PI-treated participants.

The median CA HIV RNA and total HIV DNA levels in the AIMS cohort were 1.71 (1.25-2.01) log10copies/μg total RNA and 2.41 (1.88-2.79) log10 copies/106 PBMC, respectively. Figure 1B shows correlations of current CD4+ count, CD4+ count nadir, plasma HIV RNA zenith, and duration of continuous virological suppression prior to the measurements with CA HIV RNA and DNA. In contrast to the COBRA cohort, duration of continuous virological suppression was significantly negatively associated with both CA HIV RNA (rho=-0.35, p=0.0001) and total HIV DNA (rho=-0.25, p=0.007). Duration of cumulative virological suppression and duration of current regimen were also significantly negatively associated with both CA HIV RNA (rho=-0.26, p=0.004 and rho=-0.23, p=0.01, respectively) and total HIV DNA (rho=-0.20, p=0.03 and rho=-0.18, p=0.04, respectively), but these associations were weaker than those of the duration of continuous suppression (Figure S1). In addition, current CD4+ count and plasma HIV RNA zenith were negatively (rho=-0.21, p=0.03) and positively (rho=0.18, p=0.049) associated with CA RNA but not with total DNA (Figure 1B). As in the COBRA cohort, CA RNA and DNA strongly correlated (rho=0.54, p<0.0001) and were lower in NNRTI-than in PI-treated participants (CA RNA: 1.60 (1.18-1.99) vs. 1.88 (1.51-2.17) log10 copies/μg total RNA, p=0.007; total DNA: 2.36 (1.76-2.74) vs. 2.57 (2.22-2.98) log10 copies/106 PBMC, p=0.04).

Next, we built multivariable generalized linear models to assess the association of CA HIV RNA and DNA with ART regimens in the AIMS cohort (Figure 2B, Table S2). In addition to the same variables as for the COBRA cohort, these models included gender, plasma HIV RNA detectability, and adherence to ART. Due to co-linearity between the durations of continuous and cumulative virological suppression and the duration of current regimen, only duration of continuous suppression was included in the multivariable analysis, as its associations with HIV RNA and DNA were the strongest among these three measures. Shorter duration of continuous virological suppression prior to the measurements and PI-based ART regimen remained significantly associated with higher levels of CA HIV RNA in the multivariable analysis (duration of suppression: padj=0.04; ART regimen: padj=0.02). Shorter duration of continuous suppression was also significantly associated with higher total HIV DNA (padj=0.03), while the association of ART regimen with HIV DNA did not achieve statistical significance (padj=0.10). We also built three alternative models, in which either duration of cumulative suppression or the duration of current regimen was included instead of the duration of continuous suppression, or the duration of continuous suppression was included together with the duration of current regimen. The adjusted associations of CA HIV RNA with the ART regimen remained significant in these alternative models (Figures S2, S3).

### Sensitivity analysis and associations of individual antiretroviral drugs with CA HIV RNA and DNA in the pooled cohort

Having observed similar associations of the ART regimen with CA HIV RNA and DNA in both COBRA and AIMS cohorts, we pooled the two cohorts in order to achieve sufficient statistical power to perform a sensitivity analysis and to assess the associations of individual antiretroviral drugs with the levels of CA HIV RNA and DNA. As eleven individuals participated in both cohorts seven years apart, we excluded the second samples of these individuals from the analysis, bringing the total number of participants in the pooled cohort to 213.

As expected, both CA HIV RNA and DNA were significantly lower in NNRTI-than in PI-treated participants of the pooled cohort (p=0.0006 and p=0.01, respectively) (Figure 3A). To demonstrate that the associations of ART regimens with CA RNA and DNA also hold in those individuals who are stably suppressed on therapy, we performed a sensitivity analysis, limiting the analysis to a subset of participants with undetectable plasma HIV RNA and more than six months of continuous virological suppression on ART (n=178). In this subset, CA HIV RNA remained significantly lower in NNRTI-than in PI-treated participants (p=0.006), while a trend in the same direction was observed for total HIV DNA (p=0.05) (Figure 3B).

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/03/26/2021.03.25.21254129/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/F3)

Figure 3. 
Associations of ART regimens (NNRTI-based vs. PI-based) with the levels of cell-associated HIV unspliced RNA (US RNA) and total HIV DNA in either (A) the total pooled cohort (n=213), or (B) limiting the analysis to participants with undetectable plasma viral loads and >6 months of virological suppression on ART (n=178). (C) Differences in the levels of US RNA and total HIV DNA between participants treated with ART regimens based on efavirenz (EFV), nevirapine (NVP), or PIs in the total pooled cohort. (D) Differences in the levels of US RNA and total HIV DNA between participants treated with ART regimens based on different ritonavir-boosted PIs: atazanavir (ATZ/r), darunavir (DRV/r), or lopinavir (LPV/r) in the total pooled cohort. Units of measurement are: US RNA: log10 copies/μg total RNA, total DNA: log10 copies/106 PBMC. Levels of significance were calculated by Mann-Whitney tests or Kruskal-Wallis tests with Dunn’s post-tests, as appropriate. For three- group comparisons, Kruskal-Wallis p values are shown on top of the graphs and Dunn’s significance levels of pairwise comparisons are shown by asterisks only where significant: **, 0.001<p<0.01; *, 0.01<p<0.05. Participant numbers per regimen are indicated below the graphs.

Next, we assessed the associations of individual drugs with the CA HIV RNA and DNA levels. As the vast majority of NNRTI-treated participants received either efavirenz or nevirapine, we compared the HIV markers between these two drugs and PIs (Figure 3C). While no difference was observed in CA RNA or total DNA levels between efavirenz- and nevirapine-treated participants, CA RNA was significantly lower in participants treated with either of these drugs compared to PI-treated participants and a trend in the same direction was observed for total DNA. Finally, no differences were observed in either CA RNA or total DNA levels between three individual ritonavir-boosted PIs that were used by the majority of PI-treated participants (atazanavir, darunavir, and lopinavir) (Figure 3D). These results demonstrate that the effects of ART regimens on the CA RNA and DNA levels were ART class-specific and not drug-specific.

## Discussion

In this study, we demonstrated in two independent cohorts of individuals on suppressive ART that NNRTI-based triple ART regimens are associated with lower levels of CA HIV RNA compared with PI-based regimens. To the best of our knowledge, this is the largest study comparing CA HIV RNA levels between individuals on different ART regimens. Although several studies compared residual viremia between ART regimens and most found lower levels in NNRTI-treated than in PI-treated individuals [28], very few groups included other HIV reservoir markers in such comparisons. Nicastri et al. reported lower total HIV DNA levels in individuals treated with PI-based regimens and Sarmati et al. found no difference in HIV DNA level by regimen, despite the fact that both studies reported higher residual viremia in PI-treated individuals [31, 32]. Kiselinova et al. performed a matched case-control study comparing nevirapine and PIs for residual viremia, total and episomal HIV DNA, and CA HIV RNA and did not find differences by regimen for any of these markers [33]. Notably, the latter study matched participants for the duration of PI-based or nevirapine-based regimens, but despite this, significant differences were still observed between the nevirapine- and PI-treated groups in total ART duration and duration of plasma HIV RNA suppression. In our study, we reasoned that, in the absence of *a priori* knowledge of the factors associated with CA HIV levels, such matching, albeit potentially reducing confounding, could introduce a selective bias and the results would therefore not be representative of the total ART-treated population. Instead, we chose for a cohort study design, controlling for a number of factors in the multivariable models.

Among all demographic and clinical variables, only duration of current regimen and duration of virological suppression were associated with the ART regimen, being longer in NNRTI-than in PI-treated individuals. This can be explained by the fact that while efavirenz and nevirapine, the drugs used by the absolute majority of our NNRTI-treated individuals, were approved for medical use in the late 1990s, modern PIs like atazanavir and darunavir that were used by most of our PI-treated individuals, were only approved in the mid- or late 2000s. This means that most of the NNRTI-treated individuals in this study started ART, or switched to NNRTIs from the first-generation PIs, earlier than the PI-treated individuals. Because the HIV reservoir generally decays with time on ART [34], this association of duration of suppression with the ART regimen could have potentially confounded the association of the ART regimen with the HIV reservoir measures such as CA RNA and DNA. Indeed, we found that both these HIV markers were negatively associated with the duration of suppression in the AIMS cohort. Interestingly, low-level plasma HIV RNA detectability in that cohort was also negatively associated with the duration of suppression (Figure S4), confirming the results of a previous study [27]. However, to our surprise, no association of CA RNA or DNA with the duration of suppression was found in the COBRA cohort. One possible reason for this difference between the two cohorts is that the COBRA participants were on average much longer on ART than the AIMS participants (117.8 vs. 47.1 months of cumulative virological suppression, respectively). Decay of the HIV reservoir after ART initiation is multiphasic [35, 36], and while the long-term dynamics of CA RNA has not yet been studied in detail, reports on the dynamics of total HIV DNA and residual plasma viremia have demonstrated that these markers reach a plateau after 5-7 years of treatment [37-39]. If the same applies to CA RNA, then it may be expected that after several years on ART, this reservoir measure will also no longer depend on the time on therapy, something that we indeed observed in the COBRA cohort. Instead, in the COBRA cohort, CA RNA and especially total DNA positively correlated with the plasma HIV RNA zenith, suggesting that even after a decade of ART, the HIV reservoir size is still partly determined by its pre-therapy values. Interestingly, most proviral DNA sequences from ART-treated individuals were recently shown to match circulating HIV variants detected shortly before the start of therapy, suggesting that the HIV reservoir quickly turns over in the untreated infection and that the reservoir that persists on ART has been primarily established at the start of therapy [40-42].

Another variable that could have confounded the association of the ART regimen with the HIV reservoir measures such as CA HIV RNA is the adherence to ART. Earlier studies have reported lower adherence among individuals treated with older PI-based ART regimens [43]. However, we and others have not previously observed a difference in adherence between individuals treated with modern PI- and NNRTI-based regimens [44, 45], and in this study adherence was also not associated with the therapy regimen. We have previously shown that modest non-adherence correlates with longitudinal changes in CA RNA [46]. However, no significant association between adherence and CA RNA levels was observed in this study. Adherence was also not associated with low-level plasma HIV RNA detectability (Figure S4). The relation between adherence and CA HIV RNA or residual viremia is undoubtedly complex and deserves further research, but it must be noted that while in our previous report the adherence was measured over the one-week periods immediately prior to the HIV sampling moments, in this study we used one-month adherence measurements taken within 20 days from the sampling moments. Whether short-term adherence is more strongly associated with CA RNA levels or residual viremia remains to be studied.

Notwithstanding the associations of CA RNA with other factors, in both cohorts NNRTI-based ART was independently associated with lower CA RNA levels as compared with PI-based ART, as revealed by the multivariable analysis. This analysis revealed very similar effect sizes of the ART regimen on CA RNA in both cohorts, despite the fact that several factors, such as duration of virological suppression and the PI drugs, differed between the cohorts. On average, CA RNA levels were 1.75-2-fold lower in the NNRTI-treated participants. This confirms numerous reports that measured lower residual plasma viremia in NNRTI-compared to PI-treated individuals [28]. In fact, also in this study low-level plasma HIV RNA was more frequently detectable in PI-treated than in NNRTI-treated participants, despite no difference in therapy adherence by regimen. Notably, a recent large study of more than 12,000 participants starting ART revealed that PI-treated participants were on average 2.7 times more likely to experience virological failure compared with NNRTI-treated participants [47]. Moreover, three independent clinical trials of triple ART intensification with raltegravir have previously demonstrated much stronger increases in episomal HIV DNA in PI- compared to NNRTI-treated participants, suggesting that at “baseline”, PI-treated individuals had higher levels of residual replication [21, 22, 25]. Combined, this prior evidence and the results of this study strongly suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs. Constant low-level viral replication, even if it does not cause the development of drug resistance and therapy failure, could exert continuous pressure on the immune system and cause additional morbidity as a result of persistent immune activation, inflammation, and immunosenescence [48, 49]. Several studies have reported excess morbidity and mortality rates in infected ART-treated individuals, compared with the general population [50-52]. Although it is still unclear whether this is due to the adverse effects of the antiretroviral drugs or to the residual HIV activity, our results argue that an effort should be made to ensure HIV replication is maximally suppressed during therapy.

Replenishment of the HIV reservoir by residual virus replication has been proposed as one of the mechanisms of HIV persistence [12]. The association of the ART regimen with total HIV DNA in this study was similar to its association with CA RNA: in both cohorts, levels of total DNA were 1.8-fold lower in the NNRTI-treated participants. This suggests that persistent residual replication in the PI-treated participants may have resulted in a larger viral reservoir. However, this has to be interpreted with caution, as no single marker can at present provide a reliable estimate of the HIV reservoir size [8]. Moreover, different definitions of the HIV reservoir exist. Although total HIV DNA is mostly composed of genetically defective proviruses and thus its measurements overestimate the replication-competent reservoir [53], these defective proviruses can be transcribed, translated, and even produce defective viral particles, and therefore can contribute to chronic immune activation and inflammation despite ART [54-57]. Therefore, it has been proposed to extend the definition of the reservoir to all infected cells that can contribute to the residual HIV pathogenesis [7, 58]. Furthermore, both total HIV DNA and CA HIV RNA have been shown to predict the time to viral rebound after ART interruption [59, 60], and we recently reported that CA HIV RNA was predictive of both time to and magnitude of viral rebound after interruption of temporary ART initiated during primary HIV infection [61]. This argues that despite being partially composed of defective proviruses, the transcription-competent reservoir does reflect the replication-competent reservoir [58, 62]. In view of our present results, future studies should investigate the effects of different ART regimens on the replication-competent reservoir, as the latter is the main obstacle for the development of an HIV cure [63]. Interestingly, Li et al. demonstrated that NNRTI-treated individuals experienced a significantly longer time to viral rebound after ART interruption [60], suggesting lower replication-competent reservoirs in individuals treated with NNRTI-based ART regimens.

Our study has some limitations. First, we did not include individuals treated with INSTI-based ART, which is currently recommended as first-line therapy ([https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start)), because such individuals were rare (<5%) in the COBRA cohort and absent from the AIMS cohort. Studies in more recent cohorts are necessary to elucidate the differences in CA HIV markers between INSTI-based ART and other regimens. It must be noted that although NNRTI- and PI- based ART regimens are no longer recommended as first-line therapy in all settings, millions of infected individuals are still treated with these regimens. Thus, our results are relevant for the clinical management of these individuals. Second, although our results provide strong evidence that individuals treated with PI-based ART undergo residual HIV replication, this evidence remains indirect as direct demonstration of infection of new cells in an ART-treated individual is extremely difficult if not impossible. Therefore, although studies have used various approaches to prove or disprove the existence of residual replication on ART (reviewed in [6, 15]), all these approaches have so far been indirect. Third, although we adjusted our models for a number of clinical parameters, the observational nature of these cohorts means that residual confounding cannot be entirely excluded. For instance, PI-based regimens could have been preferentially prescribed to individuals with a worse viro-immunological profile and/or expected poor therapy adherence, because PIs impose a relatively high genetic barrier to resistance and consequently will be more “forgiving” to non-adherence. However, we did not observe any significant differences by regimen in plasma HIV RNA zenith, current and nadir CD4+ count, or therapy adherence, arguing against such “prescription bias”.

In summary, here we demonstrated in two independent cohorts that levels of HIV reservoir markers are lower in individuals treated with NNRTI- as compared to PI-based combination ART. We previously proposed CA RNA as a sensitive marker of the active HIV reservoir and residual replication [6], a role that is further reinforced by the results of this study. Monitoring of CA RNA levels to detect residual HIV activity despite ART is warranted in order to prevent possible ART complications such as persistent immune activation or therapy failure [47, 64, 65], especially in individuals treated with PI-based regimens.

## Methods

### Study participants

Participants for the COBRA cohort were recruited at two clinical sites in Amsterdam (The Netherlands) and London (UK) from ongoing prospective cohort studies on co-morbidity and aging in HIV, the AGEhIV Cohort Study in Amsterdam [50] and the POPPY study in London [66]. All participants were required to be at least 45 years of age. The study design and participant characteristics were reported previously [29]. Although most COBRA participants had two study visits within two years, for the present cross-sectional study only PBMC samples from the first study visit were used: 63 participants out of 100 were from the Amsterdam sub-cohort and 37 were from the London sub-cohort. The COBRA study was approved by the institutional review board of the Academic Medical Center and a UK Research Ethics Committee. All participants provided written informed consent.

Participants for the AIMS randomized trial were recruited at the HIV outpatient clinic of the Academic Medical Center (Amsterdam). Adherence to ART in this cohort was measured electronically using MEMS-cap pill bottles (Aardex, Switzerland), which record the moments of bottle opening. Adherence was defined as percentage of doses taken within a specified time interval (11–13 hr for twice-daily and 22–26 hr for once-daily regimens) during the assessment period. For the present study, the adherence was assessed during one-month periods that finished less than 20 days before or after the HIV sampling moments. The randomized trial, the results of which were reported previously [30], assessed the impact of a behavioral intervention to increase adherence, therefore adherence data and PBMC samples were collected at several time points. For the present cross-sectional study, for 93.3% of the participants we used the “baseline” (pre- randomization) PBMC samples and the corresponding adherence assessment data. For the remaining 6.6%, who lacked baseline PBMC samples, samples and data from the subsequent time point were used. The AIMS study was approved by the institutional review board of the Academic Medical Center, and all participants provided written informed consent.

Historical plasma HIV RNA measurements, CD4+ T-cell counts, and treatment data were retrieved from the outpatient medical records. The duration of continuous virological suppression was calculated as the duration of the latest period with undetectable plasma HIV RNA prior to the measurement, allowing isolated “blips” of 50-999 copies/mL. The duration of cumulative suppression was calculated by adding together all such periods of continuous suppression. The duration of the current regimen was calculated as the period, during which the participant had been receiving combination ART that included their current NNRTI or PI drug and no other NNRTI or PI.

### Virological measurements

Plasma HIV RNA was measured using commercial assays with detection limits of 40 or 50 copies/mL. For CA HIV RNA and total HIV DNA measurements, total nucleic acids were extracted from PBMC using the Boom isolation method [67]. Extracted cellular RNA was treated with DNase (DNA-free kit; Thermo Fisher Scientific) to remove DNA that could interfere with the quantitation and reverse transcribed using random primers and SuperScript III reverse transcriptase (all from Thermo Fisher Scientific). CA HIV unspliced RNA and total HIV DNA were measured using previously described qPCR-based methods [68, 69]. HIV DNA or RNA copy numbers were determined using a 7-point standard curve with a linear range of >5 orders of magnitude that was included in every qPCR run, and normalized to the total cellular DNA (by measurement of β-actin DNA) or RNA (by measurement of 18S ribosomal RNA) inputs, respectively, as described previously [65]. Non-template control wells were included in every qPCR run and were consistently negative. Total HIV DNA was detectable in 90.0% of participants in the COBRA cohort and in 87.8% in the AIMS cohort. CA HIV RNA was detectable in 86.9% of participants in the COBRA cohort and in 83.7% in the AIMS cohort. Undetectable measurements of CA RNA or DNA were assigned the values corresponding to 50% of the corresponding assay detection limits. The detection limits depended on the amounts of the normalizer (input cellular DNA or RNA), and therefore differed between samples.

### Statistical analysis

Variables were compared between NNRTI- and PI-based ART by using Mann-Whitney tests for continuous variables and Fisher’s exact tests or Chi-square tests for categorical variables. Strength of the associations between CA RNA or DNA and other variables was initially assessed by nonparametric Spearman or Mann-Whitney tests, as appropriate, and subsequently by fitting generalized linear models (GLM) on rank-transformed dependent variables. Binary explanatory variables were included in the models if the representation of the least frequent category was >5%. Therefore, gender and plasma HIV RNA detectability were not included in the model in the COBRA cohort. Similarly, a threshold of 5% was used for inclusion of the NRTI backbone categories in the analysis, resulting in the inclusion of three most frequent categories for each cohort. The most frequent NRTI backbone category was used as a reference category. Explanatory variables that were associated with the dependent variables with a sufficient strength (p<0.1) in univariable GLM analyses were included in multivariable models. Individual tests are described in the legends to figures and tables. Data were analyzed using Prism 8.3.0 (GraphPad Software) and IBM SPSS Statistics (version 25). All tests were two-sided. P values <0.05 were considered statistically significant.

## Data Availability

All data generated or analyzed during this study are included in the manuscript and supporting files.

## Figure legends

![Figure S1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/03/26/2021.03.25.21254129/F4.medium.gif)

[Figure S1.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/F4)

Figure S1. 
Effects of duration of cumulative virological suppression and duration of the current regimen on the levels of cell- associated HIV unspliced RNA (US RNA) and total HIV DNA in the AIMS cohort (n=124). Units of measurement are: US RNA: log10 copies/μg total RNA, total DNA: log10 copies/106 PBMC. Levels of significance were calculated by Spearman correlation analyses.

![Figure S2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/03/26/2021.03.25.21254129/F5.medium.gif)

[Figure S2.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/F5)

Figure S2. 
Regression analyses to identify variables associated with cell-associated HIV unspliced (US) RNA and total HIV DNA levels in the AIMS cohort, taking into account either (A) duration of cumulative virological suppression on ART, or (B) duration of current ART regimen, prior to the measurements. Effect sizes and 95% confidence intervals for US RNA are plotted as log10 copies per microgram of total cellular RNA and for total DNA as log10 copies per million PBMC. Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p values <0.1 in the univariable analyses were included in the multivariable analyses.

![Figure S3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/03/26/2021.03.25.21254129/F6.medium.gif)

[Figure S3.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/F6)

Figure S3. 
Regression analyses to identify variables associated with cell-associated HIV unspliced (US) RNA and total HIV DNA levels in the AIMS cohort, taking into account both duration of continuous virological suppression on ART and duration of current ART regimen, prior to the measurements. Effect sizes and 95% confidence intervals for US RNA are plotted as log10 copies per microgram of total cellular RNA and for total DNA as log10 copies per million PBMC. Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p values <0.1 in the univariable analyses were included in the multivariable analyses.

![Figure S4.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/03/26/2021.03.25.21254129/F7.medium.gif)

[Figure S4.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/F7)

Figure S4. 
Differences in duration of continuous and cumulative virological suppression, duration of current regimen, and in adherence to ART between participants with undetectable vs. low-level detectable pVL in the AIMS cohort. Levels of significance were calculated by Mann-Whitney tests.

View this table:
[Table S1.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/T2)

Table S1. 
Variables associated with cell-associated HIV unspliced (US) RNA and total HIV DNA levels in the COBRA cohort.

View this table:
[Table S2.](http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254129/T3)

Table S2. 
Variables associated with cell-associated HIV unspliced (US) RNA and total HIV DNA levels in the AIMS cohort.

## Acknowledgements

We are thankful to Gilles Darcis for helpful discussions. We would like to thank the COBRA and AIMS study groups and study participants for helping to establish these cohorts. The COBRA project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement nr. 305522. A.O.P. is supported by the grant nr. 09120011910035 from the Dutch Medical Research Council (ZonMw).

*   Received March 25, 2021.
*   Revision received March 25, 2021.
*   Accepted March 26, 2021.


*   © 2021, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)

## References

1.  1.Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382(9903): 1525–33.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(13)61809-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24152939&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000326622500031&link_type=ISI) 

2.  2.Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am 2014; 28(3): 371–402.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.idc.2014.06.001&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25151562&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

3.  3.Deeks SG, Lewin SR, Ross AL, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med 2016; 22(8): 839–50.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm.4108&link_type=DOI) 

4.  4.Jacobs JL, Halvas EK, Tosiano MA, Mellors JW. Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms. Front Microbiol 2019; 10: 2383.
    
    

5.  5.Pasternak AO, Berkhout B. What do we measure when we measure cell-associated HIV RNA. Retrovirology 2018; 15(1): 13.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12977-018-0397-2&link_type=DOI) 

6.  6.Pasternak AO, Lukashov VV, Berkhout B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 2013; 10: 41.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/1742-4690-10-41&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23587031&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

7.  7.Avettand-Fènoël V, Hocqueloux L, Ghosn J, et al. Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clin Microbiol Rev 2016; 29(4): 859–80.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiY21yIjtzOjU6InJlc2lkIjtzOjg6IjI5LzQvODU5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDMvMjYvMjAyMS4wMy4yNS4yMTI1NDEyOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

8.  8.Sharaf RR, Li JZ. The Alphabet Soup of HIV Reservoir Markers. Curr HIV/AIDS Rep 2017; 14(2): 72–81.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11904-017-0355-y&link_type=DOI) 

9.  9.Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15(8): 893–900.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm.1972&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19543283&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000268770400033&link_type=ISI) 

10. 10.Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345(6193): 179–83.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzNDUvNjE5My8xNzkiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wMy8yNi8yMDIxLjAzLjI1LjIxMjU0MTI5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

11. 11.Wagner TA, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014; 345(6196): 570–3.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzNDUvNjE5Ni81NzAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wMy8yNi8yMDIxLjAzLjI1LjIxMjU0MTI5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

12. 12.Chun TW, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115(11): 3250–5.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1172/JCI26197&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16276421&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000233022100034&link_type=ISI) 

13. 13.Lorenzo-Redondo R, Fryer HR, Bedford T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016; 530(7588): 51–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nature16933&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26814962&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

14. 14.Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477(7362): 95–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nature10347&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21849975&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000294404300038&link_type=ISI) 

15. 15.Martinez-Picado J, Deeks SG. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS 2016; 11(4): 417–23.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/COH.0000000000000287&link_type=DOI) 

16. 16.Estes JD, Kityo C, Ssali F, et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat Med 2017; 477(7362): 95–8.
    
    

17. 17.Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014; 111(6): 2307–12.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMDoiMTExLzYvMjMwNyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAzLzI2LzIwMjEuMDMuMjUuMjEyNTQxMjkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

18. 18.Bozzi G, Simonetti FR, Watters SA, et al. No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication. Sci Adv 2019; 5(9): eaav2045.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo4OiJhZHZhbmNlcyI7czo1OiJyZXNpZCI7czoxMjoiNS85L2VhYXYyMDQ1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDMvMjYvMjAyMS4wMy4yNS4yMTI1NDEyOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

19. 19.Van Zyl GU, Katusiime MG, Wiegand A, et al. No evidence of HIV replication in children on antiretroviral therapy. J Clin Invest 2017; 127(10): 3827–34.
    
    

20. 20.Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008; 105(43): 16725–30.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTA1LzQzLzE2NzI1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDMvMjYvMjAyMS4wMy4yNS4yMTI1NDEyOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

21. 21.Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16(4): 460–5.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm.2111&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20228817&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000276446800051&link_type=ISI) 

22. 22.Hatano H, Strain MC, Scherzer R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208(9): 1436–42.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jit453&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23975885&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

23. 23.Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7(8).
    
    

24. 24.McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50(6): 912–9.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1086/650749&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20156060&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000274656000019&link_type=ISI) 

25. 25.Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203(7): 960–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiq138&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21402547&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

26. 26.Geretti AM, White E, Orkin C, et al. Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. J Antimicrob Chemother 2019; 74(3): 746–53.
    
    

27. 27.Darcis G, Maes N, Pasternak AO, et al. Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy. Antimicrob Agents Chemother 2020; 64(3).
    
    

28. 28.Darcis G, Berkhout B, Pasternak AO. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs. Viruses 2020; 12(5).
    
    

29. 29.De Francesco D, Wit FW, Cole JH, et al. The ‘COmorBidity in Relation to AIDS’ (COBRA) cohort: Design, methods and participant characteristics. PLoS One 2018; 13(3): e0191791.
    
    

30. 30.de Bruin M, Hospers HJ, van Breukelen GJ, Kok G, Koevoets WM, Prins JM. Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial. Health Psychol 2010; 29(4): 421–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1037/a0020335&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20658830&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000280350600015&link_type=ISI) 

31. 31.Nicastri E, Palmisano L, Sarmati L, et al. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res 2008; 6(3): 261–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/157016208784325010&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18473790&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000256616100010&link_type=ISI) 

32. 32.Sarmati L, Parisi SG, Montano M, et al. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain. J Antimicrob Chemother 2012; 67(12): 2932–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/jac/dks331&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22915460&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

33. 33.Kiselinova M, Geretti AM, Malatinkova E, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. J Antimicrob Chemother 2015; 70(12): 3311–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/jac/dkv250&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26324076&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

34. 34.Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9(6): 727–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm880&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12754504&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000183444100027&link_type=ISI) 

35. 35.Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387(6629): 188–91.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/387188a0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9144290&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1997WX94500056&link_type=ISI) 

36. 36.Blankson JN, Finzi D, Pierson TC, et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182(6): 1636–42.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1086/317615&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11069234&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000165596100008&link_type=ISI) 

37. 37.Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105(10): 3879–84.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiMTA1LzEwLzM4NzkiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wMy8yNi8yMDIxLjAzLjI1LjIxMjU0MTI5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

38. 38.Besson GJ, Lalama CM, Bosch RJ, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis 2014; 59(9): 1312–21.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciu585&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25073894&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

39. 39.Bachmann N, von Siebenthal C, Vongrad V, et al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat Commun 2019; 10(1): 3193.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41467-019-10884-9&link_type=DOI) 

40. 40.Abrahams MR, Joseph SB, Garrett N, et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci Transl Med 2019; 11(513).
    
    

41. 41.Brodin J, Zanini F, Thebo L, et al. Establishment and stability of the latent HIV-1 DNA reservoir. Elife 2016; 5.
    
    

42. 42.Pankau MD, Reeves DB, Harkins E, et al. Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women. PLoS Pathog 2020; 16(2): e1008286.
    
    

43. 43.O’Connor JL, Gardner EM, Mannheimer SB, et al. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis 2013; 208(1): 40–9.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jis731&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23204161&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

44. 44.Pasternak AO, de Bruin M, Bakker M, Berkhout B, Prins JM. High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy. PLoS One 2015; 10(10): e0140791.
    
    

45. 45.Konstantopoulos C, Ribaudo H, Ragland K, Bangsberg DR, Li JZ. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis 2015; 2(1): ofu119.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ofid/ofu119&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25884007&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

46. 46.Pasternak AO, de Bruin M, Jurriaans S, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis 2012; 206(9): 1443–52.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jis502&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22927449&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

47. 47.El Bouzidi K, Jose S, Phillips AN, et al. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. AIDS 2020; 34(12): 1823–31.
    
    

48. 48.Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254(1): 326–42.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/imr.12065&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23772629&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

49. 49.Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS 2016; 11(2): 234–41.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/COH.0000000000000230&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26575148&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

50. 50.Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59(12): 1787–97.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciu701&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25182245&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

51. 51.Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53(11): 1120–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/cir627&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21998278&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

52. 52.Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146(2): 87–95.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/0003-4819-146-2-200701160-00003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17227932&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000243901000002&link_type=ISI) 

53. 53.Bruner KM, Murray AJ, Pollack RA, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med 2016; 22(9): 1043–9.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm.4156&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27500724&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

54. 54.Pollack RA, Jones RB, Pertea M, et al. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe 2017; 21(4): 494-506.e4.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.chom.2017.03.008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28407485&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

55. 55.Imamichi H, Smith M, Adelsberger JW, et al. Defective HIV-1 proviruses produce viral proteins. Proc Natl Acad Sci U S A 2020; 117(7): 3704–10.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMDoiMTE3LzcvMzcwNCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAzLzI2LzIwMjEuMDMuMjUuMjEyNTQxMjkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

56. 56.Imamichi H, Dewar RL, Adelsberger JW, et al. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proc Natl Acad Sci U S A 2016; 113(31): 8783–8.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiMTEzLzMxLzg3ODMiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wMy8yNi8yMDIxLjAzLjI1LjIxMjU0MTI5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

57. 57.Finzi D, Plaeger SF, Dieffenbach CW. Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis. Clin Vaccine Immunol 2006; 13(7): 715–21.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY2RsaSI7czo1OiJyZXNpZCI7czo4OiIxMy83LzcxNSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAzLzI2LzIwMjEuMDMuMjUuMjEyNTQxMjkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

58. 58.Baxter AE, O’Doherty U, Kaufmann DE. Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. Retrovirology 2018; 15(1): 18.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12977-018-0392-7&link_type=DOI) 

59. 59.Williams JP, Hurst J, Stöhr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife 2014; 3: e03821.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7554/eLife.03821&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25217531&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

60. 60.Li JZ, Etemad B, Ahmed H, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016; 30(3): 343–53.
    
    

61. 61.Pasternak AO, Grijsen ML, Wit FW, et al. Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. JCI Insight 2020; 5(6).
    
    

62. 62.Abdel-Mohsen M, Richman D, Siliciano RF, et al. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med 2020; 26(9): 1339–50.
    
    

63. 63.Pasternak AO, Berkhout B. HIV Reservoir: Finding the Right Needles in a Needlestack. Cell host & microbe 2016; 20(3): 280–282.
    
    

64. 64.Hatano H, Jain V, Hunt PW, et al. Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T cells. J Infect Dis 2013; 208(1): 50–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jis630&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23089590&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

65. 65.Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 2009; 4(12): e8490.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0008490&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20046870&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom) 

66. 66.De Francesco D, Underwood J, Post FA, et al. Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis 2016; 16(1): 617.
    
    

67. 67.Boom R, Sol CJ, Salimans MM, Jansen CL,  Wertheim-van Dillen Pm, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28(3): 495–503.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjg6IjI4LzMvNDk1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDMvMjYvMjAyMS4wMy4yNS4yMTI1NDEyOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

68. 68.Pasternak AO, Adema KW, Bakker M, et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 2008; 46(7): 2206–11.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjk6IjQ2LzcvMjIwNiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAzLzI2LzIwMjEuMDMuMjUuMjEyNTQxMjkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

69. 69.Malnati MS, Scarlatti G, Gatto F, et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc 2008; 3(7): 1240–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nprot.2008.108&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18600229&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F26%2F2021.03.25.21254129.atom)